Tenaya Therapeutics picks up $106m Series C

Tenaya Therapeutics, a biotechnology company focused on treating the cause of heart disease, has secured $106 million in Series C funding.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this